1. Show article details.

    Keryx Biopharmaceuticals Appoints John F. Neylan, MD, as Chief Medical Officer

    GlobeNewswire – 8:00 AM ET 04/23/2015

    Keryx Biopharmaceuticals, Inc. (KERX), today announced the appointment of John F. Neylan, MD to the newly created position of Chief Medical Officer. "It is my pleasure to welcome John to Keryx," said Greg Madison, President and Chief Operating Officer of Keryx. "I am honored to be joining an organization so clearly dedicated to improving the lives of those with kidney disorders," said Dr. Neylan.

  2. Show article details.

    Dyadic International Announces The Appointment Of Jack Kaye To Its Board of Directors

    PR Newswire – 4:15 PM ET 03/18/2015

    JUPITER, Fla. Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO. Mr. Kaye is a seasoned financial executive with over forty years of diversified experience. Chairman of the Board, Michael Tarnok, stated, "I worked with Jack for nearly a decade on the Keryx Board.

  3. Show article details.

    Keryx Biopharmaceuticals Announces Appointment of Greg Madison to Its Board of Directors

    GlobeNewswire – 4:55 PM ET 03/10/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the appointment of Mr. Greg Madison, the Company's President and Chief Operating Officer and incoming Chief Executive Officer, to its Board of Directors, effective March 10, 2015.

  4. Show article details.

    Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of Nephrology

    GlobeNewswire – 7:45 AM ET 03/04/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the publication of Auryxia™ data and expert analyses in two peer-reviewed journals. The publication in JASN, titled "Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD" was led by Kausik Umanath, MD, Division of Nephrology and Hypertension at Henry Ford Hospital.

  5. Show article details.

    Keryx Announces Fourth Quarter and Year-End 2014 Financial Results

    GlobeNewswire – 7:00 AM ET 02/27/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced its financial results for the fourth quarter and year ended December 31, 2014. Ron Bentsur, the Company's Chief Executive Officer, commented, "I am very proud of the entire Keryx team and all that we have accomplished.

  6. Show article details.

    Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences

    GlobeNewswire – 4:10 PM ET 02/25/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that corporate presentations will be delivered at the following upcoming investor conferences: Cowen and Company 35th Annual Health Care Conference Presenter: Greg Madison, President and Chief Operating Officer Presentation Date: Monday, March 2nd, 2015 Presentation Time: 4:50 pm ET.

  7. Show article details.

    Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial Results

    GlobeNewswire – 8:00 AM ET 02/18/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that a conference call will be held on Friday, February 27th, 2015 at 8:00 a.m. ET to discuss financial results for the fourth quarter and year-ended 2014, and a business outlook for 2015.

  8. Show article details.

    Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

    GlobeNewswire – 7:53 PM ET 01/21/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the pricing of an underwritten public offering of common stock consisting of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. J.P. Morgan Securities LLC is acting as sole book-running manager in the offering.

  9. Show article details.

    Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock

    GlobeNewswire – 4:05 PM ET 01/20/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that it has commenced a $100 million underwritten public offering of shares of its common stock. The securities described above are being offered by Keryx pursuant to a Form S-3 shelf registration statement previously filed with the Securities and Exchange Commission.

  10. Show article details.

    Keryx Biopharmaceuticals Announces Transition of Leadership

    GlobeNewswire – 10:00 PM ET 01/11/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced it will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison.

  11. Show article details.

    Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

    GlobeNewswire – 7:30 AM ET 01/07/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference, being held January 12-15, at the Westin-St. Francis Hotel in San Francisco, California. Mr. Bentsur's presentation will take place on Tuesday, January 13th at 4:00 p.m. PT.

  12. Show article details.

    Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the United States

    GlobeNewswire – 7:30 AM ET 12/22/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced it has begun shipping AURYXIA™ tablets to wholesalers in the U.S. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

  13. Show article details.

    TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors

    GlobeNewswire – 8:30 AM ET 12/17/2014

    TG Therapeutics, Inc. (TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. "We are extremely pleased to be able to add Ken to our board of directors," said Michael S. Weiss, the Company's Executive Chairman and Interim CEO.

  14. Show article details.

    Keryx Biopharmaceuticals, Inc. to Present at the Oppenheimer & Co. Inc. 25th Annual Healthcare Conference

    GlobeNewswire – 7:30 AM ET 12/08/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present at the Oppenheimer & Co. Inc. 25th Annual Healthcare Conference, taking place December 10-11 in New York City.

  15. Show article details.

    Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia(TM) (ferric citrate) Covering Orally Administrable Forms

    GlobeNewswire – 7:30 AM ET 12/04/2014

    Keryx Biopharmaceuticals, Inc. (KERX) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2, 2014. On September 5, 2014, Auryxia™ was approved by the U.S. Food and Drug Administration for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

  16. Show article details.

    Auryxia(TM) (Ferric Citrate) Phase 2 Data Published in the American Journal of Kidney Disease

    GlobeNewswire – 7:30 AM ET 12/02/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced the publication of Auryxia phase 2 clinical trial results in non-dialysis dependent chronic kidney disease patients in the American Journal of Kidney Diseases.

  17. Show article details.

    Keryx Biopharmaceuticals Announces Trade Name Auryxia(TM) for Ferric Citrate

    GlobeNewswire – 5:15 PM ET 11/17/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration has approved the trade name Auryxia™ for its FDA-approved ferric citrate.

  18. Show article details.

    Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study

    GlobeNewswire – 10:00 AM ET 11/15/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced results from a 48-week Open Label Extension safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease patients with elevated serum phosphorus levels, or hyperphosphatemia.

  19. Show article details.

    Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference

    GlobeNewswire – 8:30 AM ET 11/14/2014

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City. Mr. Bentsur's presentation will take place on Tuesday, November 18, at 10:20 a.m. ET.

  20. Show article details.

    Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results

    GlobeNewswire – 7:00 AM ET 11/06/2014

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced its financial results for the third quarter ended September 30, 2014. "The third quarter of 2014 was one of tremendous achievement at Keryx," said Ron Bentsur, Chief Executive Officer of Keryx.

Page:

Today's and Upcoming Events

  • May
    7

    KERX to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.